Ambrx Biopharma Inc.
NYSE:AMAM
28 (USD) • At close March 6, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.053 | 1.123 | 0.024 | 2.245 | 2.245 | 1.299 | 1.613 | 1.162 | 1.162 | 2.566 | 2.566 | 3.596 | 3.596 | 3.24 | 3.24 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0.053 | 1.123 | 0.024 | 2.245 | 2.245 | 1.299 | 1.613 | 1.162 | 1.162 | 2.566 | 2.566 | 3.596 | 3.596 | 3.24 | 3.24 |
| Gross Profit Ratio
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reseach & Development Expenses
| 16.269 | 14.393 | 9.75 | 10.271 | 10.271 | 18.062 | 14.704 | 16.108 | 16.108 | 11.04 | 11.04 | 5.248 | 5.248 | 4.969 | 4.969 |
| General & Administrative Expenses
| 9.41 | 5.9 | 6.065 | 5.592 | 5.592 | 4.823 | 4.396 | 4.301 | 4.301 | 4.119 | 4.119 | 1.877 | 1.877 | 1.183 | 1.183 |
| Selling & Marketing Expenses
| 0 | 0 | 1.254 | 0.682 | 0.682 | 0 | 0.958 | 0.348 | 0.348 | 0.37 | 0.37 | 0.038 | 0.038 | 0.702 | 0.702 |
| SG&A
| 9.41 | 5.9 | 7.319 | 6.274 | 6.274 | 4.823 | 5.354 | 4.649 | 4.649 | 4.489 | 4.489 | 1.914 | 1.914 | 1.884 | 1.884 |
| Other Expenses
| 0.059 | 0.01 | -1.013 | 42.932 | -0.126 | -0.144 | -0.784 | 102.956 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 25.679 | 20.293 | 16.056 | -15.944 | -15.944 | 22.885 | 19.274 | -20.696 | -20.696 | -15.224 | -15.224 | -9.493 | -9.493 | -6.276 | -6.276 |
| Operating Income
| -25.626 | -19.17 | -16.032 | -8.669 | -8.669 | -28.781 | -17.661 | -17.875 | -19.048 | -12.651 | -12.651 | -3.535 | -3.535 | -3.023 | -3.023 |
| Operating Income Ratio
| -483.509 | -17.07 | -668 | -3.861 | -3.861 | -22.156 | -10.949 | -15.39 | -16.399 | -4.93 | -4.93 | -0.983 | -0.983 | -0.933 | -0.933 |
| Total Other Income Expenses Net
| 2.785 | 1.649 | 0.803 | -1.59 | 2.798 | -7.127 | -3.399 | -0.487 | -0.487 | -0.007 | -0.007 | -2.365 | -2.365 | 0.004 | 0.004 |
| Income Before Tax
| -22.841 | -17.521 | -15.229 | -13.143 | -13.143 | -28.713 | -21.06 | -19.535 | -19.535 | -12.658 | -12.658 | -5.9 | -5.9 | -3.019 | -3.019 |
| Income Before Tax Ratio
| -430.962 | -15.602 | -634.542 | -5.854 | -5.854 | -22.104 | -13.056 | -16.818 | -16.818 | -4.933 | -4.933 | -1.641 | -1.641 | -0.932 | -0.932 |
| Income Tax Expense
| 0.148 | 0.305 | 0.073 | 0.111 | 0.111 | 0.129 | 1.587 | 1.66 | 1.173 | 0.001 | 0.001 | 0.621 | 0.621 | 0.001 | 0.001 |
| Net Income
| -22.989 | -17.826 | -15.302 | -13.254 | -13.254 | -28.842 | -22.647 | -21.194 | -19.535 | -14.505 | -14.505 | -5.554 | -5.554 | -2.718 | -2.718 |
| Net Income Ratio
| -433.755 | -15.874 | -637.583 | -5.904 | -5.904 | -22.203 | -14.04 | -18.247 | -16.818 | -5.653 | -5.653 | -1.545 | -1.545 | -0.839 | -0.839 |
| EPS
| -0.37 | -0.32 | -0.34 | -0.34 | -0.34 | -0.75 | -0.59 | -1.04 | -0.51 | -5.72 | -5.72 | -0.41 | -0.41 | -0.14 | -0.14 |
| EPS Diluted
| -0.37 | -0.32 | -0.34 | -0.34 | -0.34 | -0.75 | -0.59 | -1.04 | -0.51 | -5.72 | -5.72 | -0.41 | -0.41 | -0.14 | -0.14 |
| EBITDA
| -25.105 | -20.23 | -15.966 | -8.793 | -8.793 | -23.631 | -17.103 | -18.462 | -18.462 | -12.161 | -12.161 | -3.052 | -3.052 | -2.535 | -2.535 |
| EBITDA Ratio
| -473.679 | -18.014 | -665.25 | -3.917 | -3.917 | -18.192 | -10.603 | -15.895 | -15.895 | -4.739 | -4.739 | -0.849 | -0.849 | -0.782 | -0.782 |